Omada Health, Inc.OMDA

Omada Health, the digital chronic-care outfit, reported $78.0 million of revenue in the quarter to March 2026, yet still managed to lose $3.0 million and suck $11.8 million out of operating cash. The company’s cash pile stands at $211.8 million, but the burn is visible in the line items: net income negative, operating cash negative, and only $78,000 spent on actual hardware. The story Omada sells is behaviour change at scale; the story the 10-Q tells is a company that is still building the plane while flying it. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1611115/000161071726000205/xslF345X03.htm)

Omada’s platform pitches integrated virtual-first care for chronic conditions, with a sales pitch built around population-scale activation and evidence-based outcomes. The product pages trumpet continuous innovation and peer-reviewed results, while the same site hosts a customer carousel praising programmes that make wellness available where utilisation is limited. The disconnect is not that the product doesn’t work; it’s that the filing data shows a company still funding growth with equity-like urgency rather than cash-flow maturity. (source: Omada Platform, https://www.omadahealth.com/platform; Customers, https://www.omadahealth.com/customers)

Under the hood, Omada’s March 2026 10-Q reveals stockholders’ equity of $234.1 million against liabilities of $68.7 million, with $3.8 million tied up in inventory that actually fell by $655,000 in the quarter. R&D ran at $12.7 million, while capitalised capex was a rounding error at $78,000. Diluted EPS clocked in at negative five cents on 58.9 million shares. The cash burn is the headline, but the inventory rundown and microscopic capex tell a quieter story: Omada is optimising for growth signals, not cost discipline. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1611115/000161071726000205/xslF345X03.htm)

The next milestone is the 6 August 2026 earnings call, where management will field questions about burn, inventory velocity, and the path to cash-flow positivity. Until then, the market can watch Omada’s share register, where insiders have been active, and its cash runway, which remains comfortable but not infinite. There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. (source: Media Center, https://www.omadahealth.com/media-center-omada-health)

Omada’s research pages boast peer-reviewed outcomes, but the filing facts expose a company that is still funding tomorrow’s clinical evidence with today’s cash. The tension is not clinical efficacy; it’s whether the virtuous cycle of revenue growth, inventory turns, and cash-flow breakeven arrives before the equity runway narrows. For now, the platform story outpaces the balance sheet story, and that gap is what the 10-Q leaves visible. (source: Virtual Care Innovation & Research, https://www.omadahealth.com/research-and-innovation)